The Phase 2/3 clinical trial design is supported by data from the Phase 1 first-in-human single ascending dose study. Presentation Information Ross Moat, Chief Commercial Officer, and Dr. John Paolini ...

Key study design elements include: 177Lu-girentuximab will be administered at 1480 MBq/m² (61% of the single-agent maximum tolerated dose) every 12 weeks for up to three treatment cycles. Subsequent ...

On Wednesday, Primarius fell 9.41 per cent to close at 28.80 yuan (US$4). Semitronix slipped 4.19 per cent to 55.85 yuan, while Empyrean was down 4.01 per cent to 125.09 yuan.

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from ...

The three-drug therapy also delayed disease progression by 17.2 months, compared with 7.3 months in the placebo group, with patients also able to delay chemotherapy treatment by nearly two years ...

A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and ...

WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company, today announced successful outcomes from its ENLIGHTEN 2 Phase 3 clinical trial for LYR-210, a ...

Apple is preparing to launch several new smart home products; Apple brand loyalty remains strong in the United States despite small decline; Canalys: Global TWS market grows 18% as Apple remains ...

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of ...

Corpus Christi Marina Master Plan sees progress, larger projects still in design phase. Posted: May 28, 2025 | Last updated: May 29, 2025. None. More for You.

Background: Padeliporfin VTP has demonstrated safety and efficacy for UTUC treatment in a Phase 1 study (NCT03617003). Padeliporfin VTP is a combination product of a drug, padeliporfin administered IV ...